Presidential panel says high-priced cancer drugs harm patient care

March 13, 2018 by Dennis Thompson, Healthday Reporter

(HealthDay)—"Financial toxicity" caused by high cancer drug prices is harming people's ability to fight the dreaded disease, a new report from the President's Cancer Panel warns.

The report, released Tuesday, argues that urgent action is needed to stem the growing price tags associated with new drugs, particularly if the price doesn't match the amount of benefit the drug offers.

"Drug are accelerating far faster than costs for other components of care, which, together, can result in a significant financial burden on and their families," the three-member panel wrote. "When financial resources are strained, patients are less likely to follow treatment regimens, potentially worsening health outcomes these drugs are intended to improve."

The panel recommends a series of actions to minimize the impact of drug costs on patients while also promoting value-based pricing of newer drugs.

In 2013, paid $207,000 a year, on average, for their medications, compared with $54,100 a year in 1995, according to the report.

The panel reported that much of the increase can be attributed to new cancer drugs coming on the market.

More than half of new cancer drugs approved by the U.S. Food and Drug Administration from 2009 to 2013 were priced at more than $100,000 for one patient's treatment for a year. In 2015, cancer patients were paying from $7,484 to $21,834 a month to take new breakthrough drugs that could help them survive.

These prices are causing financial toxicity—a term the panel used to describe the negative impact of cancer care costs on the well-being and survival chances of patients.

"We have patients every day who need to take medication and may be facing very difficult decisions about whether to take their medicine as prescribed or making adjustments based on financial concerns," said Ann Geiger, an adviser to the panel. She's deputy associate director of the Healthcare Delivery Research Program at the U.S. National Cancer Institute.

PhRMA, which represents the pharmaceutical industry, responded to the panel's findings.

"Today's cancer therapies were unimaginable just a decade ago. These new therapies attack disease at the molecular level and are tailored to the unique needs of individual patients," Holly Campbell, deputy vice president of public affairs at PhRMA, said in a statement.

"Thanks to these breakthroughs, the cancer death rate in the United States has fallen 25 percent since its peak and two out of three patients diagnosed with cancer are living at least five years after diagnosis," she added.

But, "too often insurance companies don't cover the newest cancer breakthroughs and if they do, they often put all medicines to treat certain types of cancer on the highest cost-sharing tier," Campbell explained. "This concentrates costs on the sickest patients, which is the opposite of how insurance is supposed to work."

"And the cost of treatment doesn't reflect the full range of factors that contribute to the financial hardships faced by patients with cancer," Campbell added. "Research shows that physician and hospital fees, transportation expenses and the inability to work, among other medical and non-medical factors, are driving the cost burden on patients."

In the report, the panel recommends:

  • Promoting value-based pricing so that drug costs are more reflective of their benefits and effectiveness.
  • Providing patients with better information and clearer communication about the cost of their treatment options, so they can make the best-informed decisions about their care.
  • Maintaining access to high-quality health insurance that minimizes the impact of cancer on patients.
  • Stimulating competition that promotes the development of generic and biosimilar versions of pricey cancer drugs.
  • Arming the FDA with the resources needed to assess cancer drug safety and effectiveness.
  • Investing in new research that will promote the development of innovative and high-value cancer drugs.

"All Americans should have the opportunity to purchase reasonably priced, high-quality health insurance with prescription drug coverage to facilitate affordable access to cancer drugs," the report states.

The American Society of Clinical Oncology issued a statement applauding the panel "for calling for urgent collaborative action to align cancer drug prices with value."

"This is a societal problem, and our nation needs to tackle rising drug prices, together with other major drivers of increasing health care costs," the group's chief executive, Dr. Clifford Hudis, said in the statement.

The American Cancer Society agreed.

"Managing rising prices is a common struggle for cancer patients who are often unsure about what their insurance will cover or how much of the cost they'll have to shoulder," according to American Cancer Society representative Kirsten Sloan. She's vice president for public policy for the society's Cancer Action Network.

"If patients are going to maintain access to the drugs they need, there has to be a balanced approach that recognizes the need for innovation and affordability. This report offers an important starting point for a critical national conversation," Sloan said.

It's unclear how the report will be received by President Donald Trump, however. All three members of the President's Cancer Panel were appointed by former President Barack Obama.

Explore further: Doctors' group offers ideas for easing cancer costs

More information: Ann Geiger, Ph.D., M.P.H., deputy associate director, healthcare delivery research program, U.S. National Cancer Institute; Clifford Hudis, M.D., chief executive officer, American Society of Clinical Oncology; Kirsten Sloan, vice president, public policy, American Cancer Society Cancer Action Network; March 12, 2018, statement, PhRMA; March 13, 2018, "Promoting Value, Affordability and Innovation in Cancer Drug Treatment: A Report to the President of the United States from the President's Cancer Panel"

The President's Cancer Panel has more about its purpose and responsibilities.

Related Stories

Doctors' group offers ideas for easing cancer costs

July 19, 2017
(HealthDay)—New cancer drugs routinely cost $100,000 a year or more, and older cancer drugs are rising in price, too. Now, the American Society of Clinical Oncology (ASCO) has some suggestions for easing patients' money ...

Treatment costs can be another blow to cancer patients

July 27, 2017
(HealthDay)—The emotional and physical costs of cancer can be staggering. But the financial side of cancer is also a great burden, with many patients in the United States struggling to pay for treatment, new research ...

Two drugs are better than one in fight against leukaemia

March 8, 2018
Adelaide scientists have devised a way to enhance the effectiveness of a patient's leukaemia treatment by using a combination of drugs.

Financial toxicity of cancer treatment 'an underestimated problem'

March 6, 2018
Besides side effects such as hair loss and nausea, a great many cancer patients in the US have to deal with stress and anxiety as a consequence of the high costs of their treatment. Pricivel Carrera of the University of Twente ...

Three thyroid cancer drugs approved for NHS in England

February 26, 2018
Three thyroid cancer treatments have been approved for routine use on the NHS in England.

Individuals in US diagnosed with cancer are 2.7 times more likely to declare bankruptcy than individuals without cancer

December 21, 2017
As advancements in cancer therapies have been making headlines in recent years, cancer drug prices have significantly increased. The remaining question is, what are the economic impacts of the differentiations in cost of ...

Recommended for you

Eating foods with low nutritional quality ratings linked to cancer risk in large European cohort

September 18, 2018
The consumption of foods with higher scores on the British Food Standards Agency nutrient profiling system (FSAm-NPS), reflecting a lower nutritional quality, is associated with an increased risk of developing cancer, according ...

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

September 18, 2018
A little p63 goes a long way in embryonic development—and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs. But once this early work is done, p63 goes silent, sitting quietly ...

Could the zika virus fight the brain cancer that killed john McCain?

September 18, 2018
(HealthDay)—Preliminary research in mice suggests that the Zika virus might be turned from foe into friend—enlisted to curb deadly glioblastoma brain tumors.

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

September 18, 2018
International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis ...

Your teen is underestimating the health risks of vaping

September 17, 2018
Teens today are more reluctant to smoke cigarettes than their counterparts nearly three decades ago, according to a study released this summer. But parents should hold their collective sigh of relief. The study, carried out ...

Artificial intelligence can determine lung cancer type

September 17, 2018
A new computer program can analyze images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth, a new study shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.